Table 1

Causes of anti-HIV first-line therapy discontinuation in the study population (n=1,096)
Type Tot Strata n % Over strata % Over total
Adverse events (toxicity/allergy) 302 (1 death) Gastrointestinal 86 28.5% 7.8%
Hypersensitivity 28 9.3% 2.6%
Central nervous system 18 6.0% 1.6%
Hepatic 14 4.6% 1.3%
Metabolic (glucose or lipid metabolism, lipodystrophy) 34 11.3% 3.1%
Renal 13 4.3% 1.2%
Hematologic 40 13.2% 3.6%
Other 69 22.8% 6.3%
Other causes 618 Simplification 252 40.8% 23.0%
Patient’s choice 93 15.0% 8.5%
Failure 86 13.9% 7.8%
Regimen intensification 59 9.5% 5.4%
Genotype-guided switch 20 3.2% 1.8%
Low adherence 19 3.1% 1.7%
End of pregnancy 16 2.6% 1.5%
Structured interruption 13 2.1% 1.2%
Enrolment in a new prospective study 13 2.1% 1.2%
Pregnancy 12 1.9% 1.1%
Other 35 5.7% 3.2%
Non-discontinued 176 (6 deaths) N/A 176 100% 16.1%

Prosperi et al.

Prosperi et al. BMC Infectious Diseases 2012 12:296   doi:10.1186/1471-2334-12-296

Open Data